T. Rowe Price Associates
CVAC

T. Rowe Price Associates’s CureVac CVAC Stock Holding History

T. Rowe Price Associates’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,324,274
Closed -$9.79M – 2964
2023
Q4 		$9.79M Sell
2,324,274
-863,425
-27% -$4.68M ﹤0.01% 1101
2023
Q3 		$21.8M Sell
3,187,699
-376,327
-11% -$3.32M ﹤0.01% 898
2023
Q2 		$37.1M Sell
3,564,026
-249,870
-7% -$2.23M 0.01% 786
2023
Q1 		$26.6M Buy
3,813,896
+3,260,031
+589% +$28.4M ﹤0.01% 847
2022
Q4 		$3.34M Buy
+553,865
New +$4.09M ﹤0.01% 1274
2022
Q2 		– Sell
-450,642
Closed -$8.84M – 2971
2022
Q1 		$8.84M Sell
450,642
-53,506
-11% -$1.07M ﹤0.01% 1384
2021
Q4 		$17.3M Buy
504,148
+20,777
+4% +$836K ﹤0.01% 1315
2021
Q3 		$26.4M Buy
483,371
+480,297
+15,624% +$28.9M ﹤0.01% 1227
2021
Q2 		$226K Sell
3,074
-1,367,014
-100% -$137M ﹤0.01% 2681
2021
Q1 		$125M Buy
1,370,088
+102,290
+8% +$9.92M 0.01% 701
2020
Q4 		$103M Buy
1,267,798
+65,377
+5% +$5M 0.01% 718
2020
Q3 		$56M Buy
+1,202,421
New +$67.1M 0.01% 829

Other funds holding CVAC

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

T. Rowe Price Associates's CVAC Position: Q1 2024 in Review

T. Rowe Price Associates sold out of CureVac (CVAC) in Q1 2024, closing a stake of 2,324,274 shares — an estimated $9.79M sold.

T. Rowe Price Associates first reported a position in CVAC in Q3 2020 and held it in 12 quarters. The position peaked at $125M in Q1 2021. 90 funds tracked by Wall St. Rank hold CVAC as of Q1 2024.

  • T. Rowe Price Associates reported no remaining CureVac position as of Q1 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,324,274 CureVac shares in Q1 2024, an estimated $9.79M.
  • T. Rowe Price Associates first reported a position in CureVac in Q3 2020 and held it in 12 quarters.
  • T. Rowe Price Associates's CureVac position peaked at $125M in Q1 2021.
  • 90 funds tracked by Wall St. Rank held CureVac as of Q1 2024.

Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.